Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $9.75.

REPL has been the topic of a number of recent research reports. HC Wainwright upgraded Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, October 27th. Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. BMO Capital Markets cut Replimune Group from an “outperform” rating to an “underperform” rating and cut their price target for the company from $27.00 to $2.00 in a report on Wednesday, July 23rd. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Finally, Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a report on Monday, October 20th.

Replimune Group Trading Down 4.3%

Shares of NASDAQ REPL opened at $9.31 on Tuesday. The company has a market cap of $726.74 million, a price-to-earnings ratio of -2.87 and a beta of 0.79. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $5.89 and a 200-day simple moving average of $7.41.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Sell-side analysts predict that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $5.37, for a total value of $49,156.98. Following the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at approximately $721,556.16. This trade represents a 6.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Replimune Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock worth $37,372,000 after purchasing an additional 237,185 shares during the last quarter. Millennium Management LLC raised its stake in shares of Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares during the period. MPM Bioimpact LLC raised its stake in shares of Replimune Group by 3.9% in the 1st quarter. MPM Bioimpact LLC now owns 987,036 shares of the company’s stock valued at $9,624,000 after purchasing an additional 37,036 shares during the period. Parkman Healthcare Partners LLC raised its stake in shares of Replimune Group by 9.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company’s stock valued at $9,266,000 after purchasing an additional 80,640 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after acquiring an additional 119,145 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.